Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridinium cross-links of collagen

Blood

Volumn 90, Issue 9, 1997, Pages 3743-3750

  Pecherstorfer, Martin ^a   Seibel, Markus J ^b   Woitge, Henning W ^b   Horn, Eva ^b   Schuster, Judith ^b   Neuda, Jane ^b   Sagaster, Peter ^b   Köhn, Horst ^b   Bayer, Peter ^b   Thiébaud, Daniel ^b   Ludwig, Heinz ^b  

^a 1st Dept of Medicine and Oncology   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; COLLAGEN; CREATININE; DEOXYPYRIDINOLINE; PYRIDINIUM DERIVATIVE; PYRIDINOLINE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR VOLUME; URINARY EXCRETION;

EID: 0030788805     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.9.3743     Document Type: Article

References (25)

1. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041, 1974
2. Klein B, Bataille R: Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 6:273, 1992
3. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R: Risk of progression in asymptomatic multiple myeloma. Am J Med 94:57, 1993
4. Bataille R, Chappard D, Basle MF: Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies. Blood 87:4762, 1996
5. Bataille R, Chappard D, Basle M: Excessive bone resorption in human plasmocytomas: Direct induction by tumor cells in vivo. Br J Haematol 90:721, 1995
6. Fujimoto D, Suzuki M, Uchiyama A, Miyamoto S, Inoue T: Analysis of pyridinoline, a cross-linking compound of collagen fibers in human urine. J Biochem 94:1133, 1983
7. Black D, Duncan A, Robins SP: Quantitative analysis of the pyridinium cross-links of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197, 1988
8. Robins SP, Duncan A, Riggs BL: Direct measurement of free hydroxypyridinium cross-links of collagen in urine as new markers of bone resorption in osteoporosis, in Christiansen CC, Overgaurd K (eds): Osteoporosis 1990. Copenhagen, Denmark, Osteopress, 1990, p 465
9. Robins SP, Woitge H, Hesley R, Ju J, Scyodin S, Seibel MJ: Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 10:1643, 1994
10. Knmel S, Brazier M, Neri V, Picurd C, Samson L, Desmet G, Sebert JL: Multiple molecular forms of pyridinoline cross-links excreted in human urine evaluated by Chromatographic and immunoassay methods. J Bone Miner Res 10:1385, 1995
11. Salmon SE, Cussady JR: Plasma cell neoplasms, in De Vita VT, Hellmann S, Rosenberg SA (eds): Cancer: Principles and Practice In Oncology, vol 2. Philadelphia, PA, Lippincott, 1993, p 1984
12. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842, 1975
13. Taylor JA, Resnick DL, Sartoris DJ: Radiographic-pathologic correlation, in Sartoris DJ (ed): Osteoporosis: Diagnosis and Treatment. New York, NY, Dekker, 1996, p 147
14. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thürlimann B, Tubiana-Hulin M, Steinhauer EU, Eijkeren M, Huss HJ, Thiébaud D: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268, 1996
15. Robins SP, Stewart P, Astbury C, Bird HA: Measurement of the cross-link compound pyridinoline in urine as an index of collagen degradation. Ann Rheum Dis 45:969, 1986
16. Pecherstorfer M, Zimrner-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiébaud D, Ludwig H, Seibel MJ: The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80:97, 1995
17. Snapper I, Khan A: Myelomatosis: Fundamentals and Clinical Features, Baltimore, MD, University Park, 1971
18. Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldét P, Alexandre C: Mechanism of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7:1909, 1989
19. Mundy GR: Hypercalcemia revisited. J Clin Invest 82:1, 1988
20. Mundy GR: Bone Remodeling and Its Disorders. Myeloma Bone Disease, London, UK, Dunitz, 1995, p 123
21. Peacock M, Rubertson WC, Nordin BBC: Relation between serum calcium and urinary calcium with particular reference to parathyroid hormone. Lancet 1:384, 1969
22. Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M, Kuramoto A: Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of interleukin-1β osteoclast activating factor-induced bone resorption. Blood 75:715, 1990
23. Rodriguez LH, Finkelstein JB, Shullenberger CC, Alexanian R: Bone healing in multiple myeloma with melphalan chemotherapy. Ann Intern Med 76:551, 1972
24. Thornton CO, Ballester O, Green field GB: Progression of bone disease in multiple myeloma patients treated with high dose therapy and autologous stem cell transplantation. Blood 88:481a, 1996 (abstr, suppl 1)
25. Berenson JB, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernon M, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488, 1996